Actively Recruiting
Noninvasive PETCT Imaging to Detect c-Met Activation in Non-Small Cell Lung Cancer Using 18F-TSPF
Led by Xilin Sun · Updated on 2025-04-04
88
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new imaging method using an 18F labeled small molecule called 18F-TSPF, designed to detect c-Met activation status in patients with non-small cell lung cancer NSCLC. The study focuses on patients with various c-Met activation types confirmed by pathology or gene testing, aiming to assess the ability of this novel PET radiotracer to accurately identify c-Met activity and potentially select patients who may benefit from c-Met tyrosine kinase inhibitors TKIs. Participants will undergo two types of PETCT scans 18F-TSPF PETCT and 18F-FDG PETCT, performed at intervals. These imaging tests are designed to compare the specificity and accuracy of 18F-TSPF in detecting c-Met activation. The study includes follow-up assessments after the imaging procedures to monitor results and patient status. During the study, participants will receive PETCT scans and be evaluated using standardized uptake values measured one hour after tracer administration. Researchers will assess imaging results alongside clinical data to determine the tracers effectiveness. Participants must adhere to follow-up schedules and meet safety requirements, including normal organ function and ability to lie flat during scans. The total participation period varies depending on follow-up needs, with safety and imaging accuracy closely monitored throughout the trial.
CONDITIONS
Brief Title
Study on c-Met Targeted PET/CT Imaging in NSCLC
Research Team
X
Xilin Sun, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here